{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:27:39Z","timestamp":1788640059700,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Antibiotics"],"abstract":"<jats:p>VIM-type-producing Gram-negative bacteria (GNB) infections are difficult to treat. This is a retrospective single-center study of 34 patients who received cefiderocol for the treatment of VIM-type-producing GNB infections, including 25 Pseudomonas spp., 7 Enterobacterales, and 5 Achromobacter sp. Primary outcomes were clinical failure (defined as death, lack of clinical improvement, or a switch to another drug) at day 14 and 30-day all-cause mortality. The median age was 59 years (IQR 53.7\u201373.4), and the median Charlson comorbidity index was 3.5 (IQR 2\u20135). The main infections were respiratory tract infections (n = 9, 27%) and skin and soft tissue infections (n = 9, 27%). Eight patients exhibited bacteremia. In 9\/17 patients with a drainable focus, drainage was performed. The median cefiderocol treatment duration was 13 days (IQR 8\u201324). Five patients (15%) experienced clinical failure on day 14, and the thirty-day mortality rate was 9\/34 (27%); two cases occurred because of an uncontrolled infection source, and one was due to a new infection caused by the same bacteria. The other six deaths were unrelated to the index infection. Five patients experienced microbiological recurrence within three months. Susceptibility testing revealed the development of cefiderocol resistance in 1\/7 cases with persistent or recurrent positive cultures. Cefiderocol, even in monotherapy, could be considered for the treatment of VIM-type-producing GNB infections.<\/jats:p>","DOI":"10.3390\/antibiotics13090874","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:31:40Z","timestamp":1726122700000},"page":"874","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-1450","authenticated-orcid":false,"given":"Cristina","family":"Kirkegaard-Biosca","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"del Barrio-Tofi\u00f1o","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Villamar\u00edn","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-0233","authenticated-orcid":false,"given":"Nieves","family":"Larrosa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-6038","authenticated-orcid":false,"given":"David","family":"Campany","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-5909","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-4747","authenticated-orcid":false,"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Critical Care Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Sepsis Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Vi\u00f1ado","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7408-314X","authenticated-orcid":false,"given":"Laura","family":"Dom\u00e9nech","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sellar\u00e8s-Nadal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5608-3090","authenticated-orcid":false,"given":"Laura","family":"Escol\u00e0-Verg\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Infectious Diseases Unit, Internal Medicine Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-344X","authenticated-orcid":false,"given":"Nuria","family":"Fern\u00e1ndez-Hidalgo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-2702","authenticated-orcid":false,"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"CIBERINFEC, ISCIII\u2014CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., van Duin, D., and Clancy, C.J. (2023). Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis., ciad428.","DOI":"10.1093\/cid\/ciad428"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14787210.2021.1935237","article-title":"Carbapenemase producing Klebsiella pneumoniae: Implication on future therapeutic strategies","volume":"20","author":"Karaiskos","year":"2022","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e01801-18","DOI":"10.1128\/AAC.01801-18","article-title":"ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum beta-Lactamases and Carbapenemases","volume":"63","author":"Jacobs","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: An Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmi.2022.11.005","article-title":"Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: A case series","volume":"29","author":"Hoellinger","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s15010-022-01933-5","article-title":"Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections","volume":"51","author":"Gavaghan","year":"2023","journal-title":"Infection"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0147423","DOI":"10.1128\/aac.01474-23","article-title":"Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-beta-lactamase (bla(VIM)): Infection management and molecular analysis","volume":"68","author":"Vega","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_11","unstructured":"Center for Disease Control, National Healthcare Safety Network (2024, April 11). CDC\/NHSN Surveillance Definitions for Specific Types of Infections, Available online: https:\/\/www.cdc.gov\/nhsn\/."},{"key":"ref_12","unstructured":"(2024, April 11). Agency EM. Fetcroja. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e0075122","DOI":"10.1128\/aac.00751-22","article-title":"Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria","volume":"66","author":"Sempere","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/jac\/dkac080","article-title":"Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing","volume":"77","author":"Matuschek","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2024, March 28). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 14.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e0019423","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections","volume":"73","author":"Warner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/cid\/ciab888","article-title":"Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression","volume":"75","author":"Simner","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jgar.2023.06.003","article-title":"Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway","volume":"34","author":"Brakert","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e0150723","DOI":"10.1128\/aac.01507-23","article-title":"A multi-species outbreak of VIM-producing carbapenem-resistant bacteria in a burn unit and subsequent investigation of rapid development of cefiderocol resistance","volume":"68","author":"Freiberg","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Pigrau","year":"2018","journal-title":"Infection"}],"updated-by":[{"DOI":"10.3390\/antibiotics14010004","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000}}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/874\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T15:07:20Z","timestamp":1754233640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["antibiotics13090874"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13090874","relation":{"correction":[{"id-type":"doi","id":"10.3390\/antibiotics14010004","asserted-by":"object"}]},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}